Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Monthly Archives: October 2022
Global Cell Therapy Market Report (2022 to 2028) – Featuring Thermo Fisher Scientific, MaxCyte, Danaher and Avantor Among Others -…
Posted: October 13, 2022 at 2:04 am
DUBLIN--(BUSINESS WIRE)--The "Global Cell Therapy Market, By Use Type, By Therapy Type, By Product, By Technology & By Region- Forecast and Analysis 2022-2028" report has been added to ResearchAndMarkets.com's offering.
The Global Cell Therapy Market was valued at USD 14.86 Billion in 2021, and it is expected to reach a value of USD 35.95 Billion by 2028, at a CAGR of 13.45% over the forecast period (2022 - 2028).
Companies Mentioned
The cell therapy industry is being propelled forward by an increase in the number of clinical trials for cell-based treatments. As a result, global investment in research and clinical translation has increased significantly. The increasing number of ongoing clinical studies can be attributed to the presence of government and commercial funding bodies that are constantly providing funds to assist projects at various stages of clinical trials.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Therapy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research and their market shares in the respective regions were determined through primary and secondary research.
This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives.
All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Segments covered in this report
The global cell therapy market is segmented based on Use-type, Therapy Type, Product, Technology, Application, and Region. Based on Use-type it is categorized into Clinical-use, and Research-use. Based on Therapy Type it is categorized into Allogenic Therapies, Autologous Therapies.
Based on Product it is categorized into Consumables, Equipment, Systems, and Software. Based on Technology it is categorized into Viral Vector Technology, Genome Editing Technology, Somatic Cell Technology, Cell Immortalization Technology, Cell Plasticity Technology, and Three-Dimensional Technology. Based on the region it is categorized into North America, Europe, Asia-Pacific, South America, and MEA.
Drivers
The increased demand for novel, better medicines for diseases such as cancer and CVD has resulted in an increase in general research efforts as well as funding for cell-based research. In November 2019, the Australian government released The Stem Cell Therapies Mission, a 10-year strategy for stem cell research in Australia.
The project would receive a USD 102 million (AU$150 million) grant from the Medical Research Future Fund (MRFF) to encourage stem cell research in order to develop novel medicines. Similarly, the UK's innovation agency, Innovate the UK, awarded USD 269,670 (GBP 267,000) in funding in September 2019 to Atelerix's gel stabilization technologies, with the first goal of extending the shelf-life of Rexgenero's cell-based therapies for storage and transport at room temperature.
Restraints
Despite technological advancements and product development over the last decade, the industry has been hampered by a lack of skilled personnel to operate complex devices like flow cytometers and multi-mode readers. Flow cytometers and spectrophotometers, which are both technologically advanced and extremely complex, generate a wide range of data outputs that require skill to analyze and review.
There is a global demand-supply mismatch for competent individuals, according to the National Accrediting Agency for Clinical Laboratory Sciences (NAACLS). Over the next decade, the UK and Europe are expected to face a severe shortage of lab capabilities, with medical laboratories being particularly hard hit.
Market Trends
The expansion of the cell therapy market was aided by the growing frequency of chronic illnesses. Chronic illness is defined as a condition that lasts one year or more and requires medical treatment, affects everyday activities, or both, according to the US Centers for Disease Control and Prevention (CDC).
It includes heart disease, cancer, diabetes, and Parkinson's disease. Patients with spinal cord injuries, type 1 diabetes, Parkinson's disease (PD), heart disease, cancer, and osteoarthritis may benefit from stem cells.
For more information about this report visit https://www.researchandmarkets.com/r/aqmxta
Posted in Stem Cell Research
Comments Off on Global Cell Therapy Market Report (2022 to 2028) – Featuring Thermo Fisher Scientific, MaxCyte, Danaher and Avantor Among Others -…
Fighting One Disease or Condition per Day – Daily Kos
Posted: October 13, 2022 at 2:04 am
When I was young,,,
36 reasons to VOTE YES! For Your Scientist Friends
By Don C. Reed
Author, STEM CELL BATTLES, other books
http://www.stemcellbattles.com
Dear Friend of Regenerative Medicine:
For the next month, I will make available a daily summary of one aspect of stem cell researchmy laymans understanding of itdone by scientists connected to the California Institute for Regenerative Medicine (CIRM). Todays is spina bifida, tomorrow is stroke.
Mistakes are mine.
In most cases I have left out the scientists names. A few I have written about in my books, and those I felt free to credit.
All I ask is that when you step into the voting booth, please consider which political party is likely to fund such research, and vote accordingly.
Spina Bifida: total awards (3) Award value: $16,798,263
The condition is devastating, and lasts a lifetime. The baby has a part of its spine bulging out of its lower back. Accompanying symptoms are many, including: headaches, vomiting, weakness in the legs, bladder and bowel problems.
Current standard of care (in utero surgery) leaves 58% of patients unable to walk independently.
39% of affected population are Hispanic or Latino descent.
The condition may cost several million dollars per patient, over his or her lifetime.
Spina Bifida (SB) appears to be caused by a combination of genetic and environmental conditions, but no one is sure. How will CIRM fight such a thing?
One way is Placenta-derived mesenchymal stem cells, seeded on a Cook Biodesign extracellular Matrix. Think of a mesh screen, over the wound.
THERAPEUTIC MECHANISM: Mesenchymal stem cellssecrete growth factors (and) cytokinesprotecting motor neurons from cell deathtreatment increases the density of motor neurons in the spinal cord, leading to improved motor functionultimately reducing lower limb paralysis. (1)
Grant recipient Diana Farmer began science as a marine biologist, who doing research at the famous Woods Hole Institute. On the way to receive an award, she suffered a car accident, and changed her mind, working on human biology. She was the first woman to perform surgery on a baby in its mothers womb. (1)
She and Aijun Wang received a CIRM grant to co-launch the worlds first human clinical trial using stem cells to treat spina bifida.. (2)
Posted in Stem Cell Research
Comments Off on Fighting One Disease or Condition per Day – Daily Kos
The Issue of Tissue: Getting to the Source of the HIV Reservoir – amfAR, The Foundation for AIDS Research
Posted: October 13, 2022 at 2:04 am
Not all stem cell transplants in individuals living with HIV and cancer, such as those used to cure Timothy Ray Brown and Adam Castillejo, among others, have been successful. Yet much can be learned about curing HIV from those whose lives could not be saved.
Research questionCurrently the only curative intervention for HIV is to transplant donor cells with a CCR5 delta32 genetic mutation in a person living with HIV (PLWH). But the impact of such transplants on HIV reservoirs in various organs has not been extensively characterized. A consortium of European researchers known as IciStem, established through amfAR funding, sought to gauge this impact by studying autopsy specimens from two individuals who underwent such transplants but were not cured and died soon afterwards.
FindingsThe first individual had been infected with HIV for 14 years and treated with antiretroviral therapy (ART) for that entire period. He was given a transplant in an attempt to cure a blood disorder known as MDS. On the 36th day following that procedure he achieved 100% chimerism. That meant that all his newly formed immune and other blood cells were the offspring of the donor and should be resistant to HIV infection. However, 29 days later that 100% value fell to 85%presumably related to an initially undetected population of recipient cells that were not destroyed by the transplant preparation procedure. He died of severe sepsis. At that time his blood still had no evidence of HIV, but all organs sampled, from brain to lymph node, showed signs of persistent infection.
The second individual had been infected with HIV for 22 years and treated with ART for the last 19 years. He required two transplants in an attempt to cure his acute leukemiathe first one having failed to take holdand on the 100th day following the first transplant (29 days after the second procedure) he achieved 100% chimerism. However, he died of lung failure eight days later. At that time no virus could be found in the blood, but the lymph node and spleen showed persistence of an HIV reservoir.
ImpactThe authors emphasize the need for examining tissues, not just blood, of PLWH having undergone potentially curative interventions as their results document that [t]issues play an essential role as a long-standing viral reservoir and routine [blood] sampling in living HIV-1-individuals will be insufficient to represent the extent of this reservoir.
amfARs roleamfAR was a funder of this research.
Original articlehttp://www.ncbi.nlm.nih.gov/pubmed/36146874
Dr. Laurence is amfARs senior scientific consultant.
See the article here:
The Issue of Tissue: Getting to the Source of the HIV Reservoir - amfAR, The Foundation for AIDS Research
Posted in Stem Cell Research
Comments Off on The Issue of Tissue: Getting to the Source of the HIV Reservoir – amfAR, The Foundation for AIDS Research
Cell Isolation Global Market Report 2022: Significant Growth in the Medical and Pharmaceutical Industries Driving Sector – ResearchAndMarkets.com -…
Posted: October 13, 2022 at 2:04 am
DUBLIN--(BUSINESS WIRE)--The "Cell Isolation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global cell isolation market size reached US$ 10.3 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 24.6 Billion by 2027, exhibiting a CAGR of 15.62% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Cell isolation, or separation, refers to the process of identifying and removing one or more specific cells from a heterogeneous mixture of cell population. The targeted cells are identified, isolated and separated according to their type. Some commonly used methods for cell isolation include magnet-activated cell separation, filtration, centrifugation and flow cytometry.
Cell isolation is also used to diagnose diseases, cellular research and therapies by analyzing the ribonucleic acid (RNA) expressions. It aids in minimizing experimental complexity while analyzing the cells and reducing the interference from other cell types within the sample. As a result, it finds extensive application in cancer research, stem cell biology, immunology and neurology.
Cell Isolation Market Trends:
Significant growth in the medical and pharmaceutical industries is one of the key factors creating a positive outlook for the market. Furthermore, increasing emphasis on cell-based research is providing a thrust to the market growth. Researchers actively utilize isolated cells to develop novel cell therapies and cell-based treatments for various chronic medical ailments. Pharmaceutical manufacturers are also widely using cell isolation technologies to improve drug discovery and develop drugs with enhanced efficacies. In line with this, the increasing requirement for personalized medicines is also contributing to the growth of the market.
Additionally, the development of advanced separation tools for proteins, nucleic acids, chromatin and other complex cells for subsequent analysis is also contributing to the growth of the market. Other factors, including extensive research and development (R&D) activities in the field of biotechnology, along with the implementation of favorable government policies, are anticipated to drive the market toward growth.
Key Market Segmentation
Breakup by Technique:
Breakup by Cell Type:
Breakup by Product:
Breakup by Application:
Breakup by End Use:
Breakup by Region:
Key Questions Answered in This Report:
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
5 Global Cell Isolation Market
6 Market Breakup by Technique
7 Market Breakup by Cell Type
8 Market Breakup by Product
9 Market Breakup by Application
10 Market Breakup by End Use
11 Market Breakup by Region
12 SWOT Analysis
13 Value Chain Analysis
14 Porters Five Forces Analysis
15 Price Analysis
16 Competitive Landscape
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/8hx8ne
Posted in Stem Cell Research
Comments Off on Cell Isolation Global Market Report 2022: Significant Growth in the Medical and Pharmaceutical Industries Driving Sector – ResearchAndMarkets.com -…
Celebrating 20 years of discovery, Picower Institute looks ahead to continuing impact – MIT News
Posted: October 13, 2022 at 2:03 am
If ever there was an event that would seem designed for dwelling on the past, it would be the anniversary celebration of an institute centered on the study of memory, but the first of many insights offered by the 20th Anniversary Exhibition of The Picower Institute for Learning and Memory at MIT Sept. 22 was that memory is all about the future.
Ever since University of California at Berkeley psychology professor David Foster was a postdoc in the Picower Institute lab of Fairchild Professor Matthew Wilson, his research has employed sophisticated neural recordings and behavioral experiments showing that animals dont just store memories of the spaces and objects around them. In the first talk of the day, Foster demonstrated that during periods of rest animals often think about where they might want to go and rehearse possible future routes in their mind. In other words, much like people do, they use past memory of their experiences to consider how to move forward in the future.
Picower professor Susumu Tonegawa, who founded MITs Center for Learning and Memory in 1994 and worked with the Picower family to create the Picower Institute in 2002, spoke right after Foster. He described new research led by postdoc Afif Aqrabawi showing how the brain physically turns individual memories of experience into generalizable knowledge for use in the future. Tonegawa offered the example of restaurant dining. After a few delicious dinners, you learn the general idea of what to expect the next time. A decade ago Tonegawas lab showed how individual event memories are represented by connected ensembles of neurons called engrams. A key ingredient of Aqrabawis new findings is that generalized knowledge arises from the activity of neurons that inhabit the overlap of related engrams. Essentially, they enable the brain to represent the similarities among single experiences that compose knowledge.
Susumu Tonegawa discusses his lab's research on how individual memories are integrated to produce generalized knowledge.
Photo: Faith Ninivaggi
Just as the meaning of memory is to inform the future, a clear message of the symposium was that the last two decades of the Picower Institutes research, discoveries, and innovations, as well as the training it has provided to hundreds of scientists who have carried on independent careers, are helping to shape the present and future of neuroscience, medicine, and industry.
Each of the Picower Institutes 13 labs were represented through talks delivered by the primary investigator, a current trainee, or a member of Picowers growing alumni community. As Picower professor and institute director Li-Huei Tsai framed it for the hybrid audience of about 1,700 people, Each of todays talks will illustrate in different ways the impact of our research and training on current questions across many areas of neuroscience.
MIT President L. Rafael Reif, in a prerecorded message, presaged the broad and urgent significance of the research those talks would cover when he praised the Picower Institute as a brilliant collective of scientists who work together to help us better understand ourselves and to advance solutions that offer people with brain disorders real, practical hope.
Reif and Tsai also led many speakers in thanking Barbara Picower, president of the JPB Foundation, not only for the gift she and her late husband Jeffry gave back in 2002, but for continued support, vision, and insight ever since.
In her remarks, Picower reflected those expressions of gratitude back on the researchers.
I am only an enabler, she said. It wouldnt matter how much money anybody put into the institute if we didnt have great scientists doing great work. So I would like to turn this around a little bit and say thank you to our scientists, many of them who have also been at the institute for 20 years or more.
Impacts at Picower
One of those long-tenured scientists is Picower professor Earl K. Miller, whose talk took on a past-and-future theme explicitly. He described his labs 27-year journey from a time when neuroscientists thought the brain worked like clockwork individual parts all playing single, distinct roles to the modern era, where advances in technology and understanding have revealed that amazing cognitive abilities such as working memory, prediction, categorization, and attention emerge from the brains ability to process information through dynamically assembled networks. His work, for instance, has shown that neurons can take on multiple roles and that brain waves of particular frequencies can assemble and coordinate ensembles of neurons as needed to sculpt the flow of information across the brains cortex. Hardwired connections, therefore, represent possible routes for information flow, but dont determine it.
The Picower Institute: 20 Years of Discovery & Impact
In fact, Lister Brothers Associate Professor Steve Flavell noted that while his labs model organism, the C. elegans worm, is the only animal on the planet whose whole neural wiring diagram has been mapped out, it is still capable of producing a rich and flexible repertoire of behaviors. He described how his lab has developed advanced microscopy and computational techniques to enable unprecedentedly comprehensive correlations of the little animals neural activity and behavior. That in turn has allowed him to demonstrate fundamental principles of how nervous systems can account for many variables, such as internal states and environmental conditions, to generate situationally appropriate behaviors even from hardwired circuits.
Jeongtae Kwon, a postdoc in the lab of Mark Hyman Jr. Associate Professor Gloria Choi, described a vivid new example of behavioral flexibility in mice. He recently led a study showing that while male mice have a powerful mating instinct, a circuit connecting olfactory regions with a brain region called the amygdala will override that instinct if a potential mating partner smells like she is sick. Essential to this social distancing circuits function is the presence of the neuromodulatory chemical TRH. Kwon is planning to continue his work when he starts his own lab in Korea in October.
Picower researchers are not only illuminating how the brain produces knowledge, cognition, and behavior, but also consciousness. Representing the lab of Emery N. Brown, Edward Hood Taplin Professor of Medical Engineering and Computational Neuroscience, graduate student Indie Garwood described how the lab has shown how ketamine general anesthesia works. Theyve found that it promotes an unusual signature of gamma wave activity that disrupts consciousness and that the waves arise from how the drug promotes elevated production of the neuromodulatory chemical acetylecholine. Such findings point to new ideas for the future, she said, including improving monitoring anesthesia in the operating room, improving understanding of how ketamine affects the brain at a systemic level, and understanding more about how drugs like ketamine affect consciousness.
Brown lab graduate student Indie Garwood makes a point during her talk about the mechanisms of ketamine general anesthesia in the brain.
Photo: Faith Ninivaggi
In his talk, Newton Professor Mriganka Sur traced an arc of his labs 30 years of research from the past to the future, showing how fundamental research can lead to the development of clinical treatments. Beginning with a revolutionary study in which he demonstrated the brains plasticity by showing how a developing ferrets brain would repurpose the auditory cortex to augment the visual cortex if cut off from input from the ears, Surs lab has gone on to study cortical plasticity intensely. His lab has produced powerful demonstrations of how neural activity changes with learning and how individual neural connections, or synapses, change to enable such adaptive flexibility. He also described how such investigations have revealed a promising treatment for Rett syndrome: In 2009 the lab showed how a protein that is crucial for regulating synaptic plasticity is lacking in the developmental condition and that many symptoms can be improved with doses of the protein called IGF-1. A company that has run with the idea has now successfully completed phase 3 clinical trials and asked the FDA to approve the treatment.
We expect that IGF-1 peptide, with two methyl groups added so that it is bioavailable longer, will be approved as the first thereapeutic for any neurodevelopmental disorder, Sur said.
Ever since Associate Professor Myriam Heiman joined the institute in 2011, her research has been guided by the principle that fundamental understanding can lead to breakthroughs in addressing disease. She focused her talk on a new, highly emblematic and collaborative study led by grad student Francisco Garcia. Using several innovative techniques, the research not only produced the first comprehensive map of the cell types that make up the brains blood vessels, but also identified specific ways in which the integrity of the blood-brain barrier unravels in Huntingtons disease. Because blood-brain barrier deficiencies are noted in many other diseases, she said, the findings could help address many disorders.
Impact beyond
As much as the Picower Institute contributes to the field through research in its labs, it also contributes by training researchers, like Foster and Kwon, who then establish their own. When he was a postdoc in Tsais lab, for example, Joel Blanchard engineered a cutting-edge model of the human blood-brain barrier using stem cells to investigate the effects of an Alzheimers disease risk gene. Now an assistant professor at Mt. Sinai, he continues to use stem cells to study aging and neurodegenerative disease. In his talk, Blanchard described a new study in which his lab used stem cells to model the pathology of a gene mutation that causes a rare juvenile form of Parkinsons disease. The models have revealed that the mutation causes cells called astrocytes to become toxic to neighboring dopamine-producing neurons and have helped the lab identify a drug that can prevent the adverse pathology.
Much as Blanchard has continued his neurodegeneration work, Ben Auerbach, an alumnus of the lab of Picower professor Mark Bear, has continued to study autism in his lab as an assistant professor at the University of Illinois. Auerbach described how his team has used rats modeling Fragile X syndrome to understand, at multiple levels of brain physiology, how the genetic mutation underlying the disease produces a symptom common across many autism spectrum disorders: sensory hypersensitivity. Hes found that it derives from hyperactivity among neurons in the auditory cortex and shown that chemically intervening to promote inhibition reduces auditory hypersensitivity.
In his talk, Boston University Assistant Professor Jerry Chen discussed how his lab has been developing technologies to allow measurements spanning neural gene expression, connectivity, activity, and animal behavior to produce vertically integrated insights for every animal subject in the lab. Earlier this year, the lab used the approach to identify and characterize the key role a previously unknown type of neuron plays as a hub of cortical circuits enabling sensory processing in mice. As he spoke, he traced roots of the success back to both technologies and scientific ideas he learned when he was in the Picower lab of William R. and Linda R. Young Professor Elly Nedivi.
There is, of course, no requirement at all that alumni carry on their research with such clear continuity. Sometimes the training and exposure they gain at the Picower Institute proves just as valuable for launching into distinct career territory.
For example, Sung-Yon Kim, now a professor at Seoul National University, was the first postdoc in the Picower Institute and chemical engineering lab of Kwanghun Chung. In Chungs lab, Kim contributed to developing innovative technologies for clearing, labeling, preserving, imaging, and analyzing brains and other tissues. But in his own research hes making discoveries about something quite different: identifying the neural and circuit mechanisms that underlie survival behaviors including finding warmth and regulating eating.
And Zacchary Piccioli, an alumnus of the lab of Menicon Professor Troy Littleton, didnt speak about neuroscience at all. Instead, as a director of R&D strategy at Moderna, he discussed how the company hopes to use the distinct advantages inherent in mRNA vaccines (like the companys highly successful Covid-19 vaccines) in the fight against other infectious diseases such as influenza.
I think Zach is a really wonderful example of how Picower alumni have impacts beyond just the field neuroscience including in clinical therapeutics, Littleton said.
Right before she closed the day, inviting viewers and attendees to the unveiling of the new painting Learnings and Memories by artist Mila Sheng in the Picower Institute lobby, MIT School of Science Dean Nergis Mavalvala noted that a particular excitement she finds in science is that finding the answers to research questions often yields new questions that evoke further discovery. There will always be more to learn.
Were not only celebrating the past 20 years of Picower Institute history but we are also kicking off the next 20 years of discovery and impact, Mavalvala said. The quest goes on.
Mila Sheng (in white) looks on as Picower Institute staff members David Orenstein and Will Lawson drop a cloth to unveil "Learnings and Memories," a painting exploring multiple scales of neurosicence imagery in the lobby of The Picower Institute.
Photo: Faith Ninivaggi
More here:
Celebrating 20 years of discovery, Picower Institute looks ahead to continuing impact - MIT News
Posted in Illinois Stem Cells
Comments Off on Celebrating 20 years of discovery, Picower Institute looks ahead to continuing impact – MIT News
Weekly Roundup: FAO Food Price Index drops for sixth consecutive month, BlueNalu’s new alt-seafood facility – Food Ingredients First
Posted: October 13, 2022 at 2:03 am
07 Oct 2022 --- This week in industry news, the gauge for world food commodity prices declined for the sixth month in a row in September. BlueNalu revealed its plans to increase profitability with its first large-scale facility for cell-based seafood. Sensient Technologies acquired natural colors and extracts manufacturer Endemix, while Solina continues its expansion of sauces and dressings in North America. Fresh Del Monte and Decapolis joined forces to provide industry-wide blockchain traceability solutions. Meanwhile, Beneo opened an additional rice starch production line which it touted to increase production capacity to 50%.
In brief: Business movesAccording to a report released by the Food and Agriculture Organization of the United Nations (FAO), prices of vegetable oils have lead the decline in food prices as of late. The FAO Food Price Index averaged 136.3 points in September, down 1.1% from August while remaining 5.5% higher than its value a year earlier. The Index tracks monthly changes in the international prices of a basket of commonly traded food commodities. The FAO Vegetable Oil Price Index drove the decline, decreasing by 6.6% over the month to reach its lowest level since February 2021. International quotations for palm, soy, sunflower and rapeseed oils were all lower. Lingering heavy inventories of palm oil, coinciding with seasonally rising production in Southeast Asia, pushed palm oil prices down. Higher soy oil export availabilities in Argentina, increased sunflower oil supplies from the Black Sea region and lower crude oil prices also contributed to the drop in this subindex.BlueNalu is on a track to significant profitability with the launch of its first large-scale facility for cell-based seafood, partly due to a series of breakthrough technologies. These technologies are expected to reduce both operating and capital costs for large-scale production drastically, while enabling a projected 75% gross margin. The companys first product will be bluefin tuna toro, a highly prized and specialty portion that commands premium pricing across global markets. Commonly known challenges include scalable cell growth technologies; the development of food-grade raw materials;BlueNalu is on track to significant profitability with the launch of its first large-scale facility.production methods that enable regulatory approval and consumer adoption; and processes that support continuous volume production. Given these challenges, species selection, product format and market fit are critical factors in the profitability equation.
Fresh Del Monte Produce has invested a 39% stake in Decapolis. This Jordanian and UK-based start-up company provides blockchain-driven food safety and quality traceability technology for the F&B industry. The two companies plan to roll out Decapolis Food Guard (DFG), the blockchain-based traceability solution, across all Fresh Del Monte business segments, starting with Fresh Del Montes pineapple operations in Costa Rica. Decapolis Food Guard provides full traceability solutions through the DFG chain of records which capture assessments at each stage of production, from planting to distribution through QR codes.
Steakholder Foods has filed a provisional patent application with the US Patent and Trademark Office, regarding methods and systems for adipocyte differentiation. The patent application details a new and improved process for differentiating stem cells into fat (increasing cultivated fat yields from stem cells), which is more easily reproducible and cost-effective than current methods. This patent filing is the latest step in Steakholder Foods push to reduce global dependence on animal-derived components. To date, Steakholder Foods patent portfolio fully owned by Steakholder Foods group companies includes a granted patent and 15 patent applications.
Beneoopened its new rice starch production line with a special inauguration event. The addition of the new line increases production capacity at the suppliers Wijgmaal facility in Belgium by 50%, allowing the company to continue meeting the growing demand for its clean label rice ingredients. Beneo is a global provider of rice flour, starch and protein for the food and feed industry, and the companys unique rice derivatives are used in producing a wide range of clean label products. The increasing demand for natural and clean label ingredients has led to Beneos production line expansion in a wide range of applications. Beneo is a global provider of rice flour, starch and protein for the food and feed industry.
In brief: Acquisitions Sensient Technologies has acquired Endemix Doal Maddeler(Endemix). Endemix, located in Turkey, is a vertically integrated natural color and extract company servicing the food and beverage markets. The acquisition of this business strengthens Sensients extensive natural color portfolio capabilities and puts Sensient operations closer to key botanical growing areas. Sensient will continue to focus on natural solutions to support its customers in meeting demands for healthier, cleaner products.
Solina, a European producer of savory ingredient solutions, has signed an agreement to acquire Saratoga Food Specialties to continue its expansion in North America. The regulatory approval process is underway and the transaction is expected to close at the end of October 2022. With US-based operations in California, Illinois and Nevada, and annual sales of US$280 million, Saratoga supplies Quick Service Restaurants and food manufacturers with custom dry seasoning blends and liquid solutions such as sauces, dressings and glazes. Upon closing, the Saratoga leadership team and its 500 employees will join Solina.
Puratos UK has bolstered its portfolio of locally made products following the acquisition of fruit grower and processor Fourayes. The move underlines the bakery and patisserie ingredient specialists commitment to future generations through responsible, transparent and local sourcing. The Puratos local and transparent fruit sourcing program aims to embed sustainability through the entire value chain, from sourcing of raw materials to usage of products by customers and consumers. Fourayess range of fruit fillings, industrial jams and mincemeat will complement and enhance Puratoss existing local fillings capabilities in Simonswood, further expanding the offer of locally-produced ingredients to customers.
In brief: Miscellaneous highlightsAleph Farms has announced the addition of Kevin Benmoussa as its executive VP and chief financial officer. Based in Aleph Farms US headquarters in New York Citys historic Meatpacking District, Benmoussa will lead the companys global growth agenda, spearhead its operational expansion in the US, and oversee finance, administration and legal departments globally for the company.
CuliNEX, a US clean label food product and plant-based formulation consultancy, has revealed that Jenny Holman has joined the team as a new project manager. Holman will immediately immerse herself in client projects, launching in with her new colleagues to lead and execute clean label innovations for clients.
Kerrygoldhas launched a one-of-a-kind experience that brings recipes to life through fable-like stories. The Magical Pantry helps families cook together through an innovative digital platform thatThe makers of Hormel Black Label bacon brand are celebrating National Sausage Month during October.integrates recipes seamlessly into childrens stories so kids can learn and practice cooking skills every time they read. The Magical Pantry, designed for both desktop and mobile, lets young families fully customize a character, pick from almost 40 recipes and select one of 4 unique fables to read and enjoy.
The makers of Hormel Black Label bacon brand are celebrating National Sausage Month during October. The brand team heard the pleas of sausage lovers far and wide and is bringing back its Little Sizzlers original pork sausages at select US retail locations.
By Elizabeth Green
To contact our editorial team please email us at editorial@cnsmedia.com
If you found this article valuable, you may wish to receive our newsletters. Subscribe now to receive the latest news directly into your inbox.
View original post here:
Weekly Roundup: FAO Food Price Index drops for sixth consecutive month, BlueNalu's new alt-seafood facility - Food Ingredients First
Posted in Illinois Stem Cells
Comments Off on Weekly Roundup: FAO Food Price Index drops for sixth consecutive month, BlueNalu’s new alt-seafood facility – Food Ingredients First
Cornell Prof Explains Relevance of Creating Mouse Embryos from Stem Cells – Cornell University The Cornell Daily Sun
Posted: October 13, 2022 at 2:02 am
In August 2022, NIH researchers from the University of Cambridge successfully created a synthetic mouse embryo model using cultured mice stem cells. This project aimed at using stem cells to express specific genes that would lead to the development of these mouse stem cells into embryos.
Stem cells are undifferentiated cells that developed into specialized cells with specific functions.
Prof. John Schimenti, biomedical sciences, explained the processes involved in this project as well as its implications for the future of scientific research.
There are many different types of stem cells and the relevant type for these experiments are called embryonic stem cells. These are totally undifferentiated and in the right context, could make all cells in the body by giving rise to more differentiated cells, Schimenti said.
The stem cells are placed in a culture medium, which optimizes their growth by stimulating cell-to-cell communication. This communication is necessary because cells use signaling during embryonic development.
This system of cell communication as a means of embryonic development is similar to the process of natural embryonic development in mammalian pregnancies such as humans.
During fertilization, the fertilized eggs cells divide into an embryo as it implants into the uterus.
Scientists had applied this knowledge by taking embryonic stem cells extracted in the lab and combining them with these early embryos. They were then placed in the uterus of a mouse subject and the resulting fetus contained cells that were partly, if not entirely, from the stem cells.
While the fetus develops, the mother starts to grow a new organ called the placenta, which supplies the fetus with the necessary nutrients as well as oxygen and glucose. The placenta guides the development of organs, acts as an immunological barrier to protect the fetus against infections, and synthesizes fatty acids and cholesterol, among other critical functions.
However, scientists found it challenging to mimic this natural environment in a petri dish because there was no placenta, which would have normally supplied the right balance of nutrients to the developing embryo.
To direct the development of the synthetic embryo, the researchers in this project started with embryonic stem cells that were completely undifferentiated. They then differentiated some of them into two different cell types by adding the corresponding developed cells.
The first group of differentiated cells would ultimately form the placenta and the other would become the yolk sac, a membranous structure attached to an embryo where the embryos first blood cells are made.
There are three different types of cells present: the unadulterated embryonic stem cells and the two partially differentiated helper tissues. They are mixed together after doing experiments to figure out the right ratios of factors like gas and nutrient levels, Schimenti said.
The project, starting in 2012, culminated in a synthetic embryo with a semi-functioning brain and heart. The organs were semi functioning because while they did work, they were not enough to independently sustain life.
This outcome significantly adds to the understanding of not only stem cells but the science of embryonic development because it allows scientists to experiment with embryonic development in real time. The University provides a unique opportunity to engage more with these concepts through its initiatives for stem cell research such as the Ansary Center for Stem Cell Therapeutics and the later established Cornell Stem Cell Program.
Moving forward with this breakthrough, researchers at the University continue to refine the different aspects of stem cell research by pushing development further and improving the efficiency of the organs being developed.
Despite this scientific breakthrough, there is still more to contribute in the study of the relationship between stem cells and regenerative medicine.
View original post here:
Cornell Prof Explains Relevance of Creating Mouse Embryos from Stem Cells - Cornell University The Cornell Daily Sun
Posted in Stem Cells
Comments Off on Cornell Prof Explains Relevance of Creating Mouse Embryos from Stem Cells – Cornell University The Cornell Daily Sun
Human neuron clusters transplanted into rats offer new tool to study the brain : Shots – Health News – NPR
Posted: October 13, 2022 at 2:02 am
This cross-section of a rat brain shows tissue from a human brain organoid fluorescing in light green. Scientists say these implanted clusters of human neurons could aid the study of brain disorders. Pasca lab / Stanford Medicine hide caption
This cross-section of a rat brain shows tissue from a human brain organoid fluorescing in light green. Scientists say these implanted clusters of human neurons could aid the study of brain disorders.
Scientists have demonstrated a new way to study conditions like autism spectrum disorder, ADHD, and schizophrenia.
The approach involves transplanting a cluster of living human brain cells from a dish in the lab to the brain of a newborn rat, a team from Stanford University reports in the journal Nature.
The cluster, known as a brain organoid, then continues to develop in ways that mimic a human brain and may allow scientists to see what goes wrong in a range of neuropsychiatric disorders.
"It's definitely a step forward," says Paola Arlotta, a prominent brain organoid researcher at Harvard University who was not involved in the study. "The ultimate goal of this work is to begin to understand features of complex diseases like schizophrenia, autism spectrum disorder, bipolar disorder."
But the advance is likely to make some people uneasy, says bioethicist Insoo Hyun, director of life sciences at the Museum of Science in Boston and an affiliate of the Harvard Medical School Center for Bioethics.
"There is a tendency for people to assume that when you transfer the biomaterials from one species into another, you transfer the essence of that animal into the other," Hyun says, adding that even the most advanced brain organoids are still very rudimentary versions of a human brain.
The success in transplanting human brain organoids into a living animal appears to remove a major barrier to using them as models of human disease. It also represents the culmination of seven years of work overseen by Dr. Sergiu Pasca, a professor of psychiatry and behavioral sciences at Stanford.
Human brain organoids are made from pluripotent stem cells, which can be coaxed into becoming various types of brain cells. These cells are grown in a rotating container known as a bioreactor, which allows the cells to spontaneously form brain-like spheres about the size of a small pea.
But after a few months, the lab-grown organoids stop developing, says Pasca, whose lab at Stanford devised the transplant technique. Individual neurons in the cluster remain relatively small, he says, and make relatively few connections.
"No matter how long we keep them in a dish, they still do not become as complex as human neurons would be in an actual human brain," Pasca says. That may be one reason organoids have yet to reveal much about the origins of complex neuropsychiatric disorders, he says.
So Pasca's team set out to find an environment for the organoids that would allow them to continue growing and maturing. They found one in the brains of newborn rats.
"We discovered that the [organoid] grows, over the span of a few months, about nine times in volume," Pasca says. "In the end it covers roughly about a third of a rat's hemisphere."
The transplanted cells don't seem to cause problems for the rats, who behave normally as they grow, Pasca says.
"The rat tissue is just pushed aside," he says. "But now you also have a group of human cells that are integrating into the circuitry."
The human cells begin to make connections with rat cells. Meanwhile, the rat's blood vessels begin to supply the human cells with oxygen and nutrients.
Pasca's team placed each organoid in an area of the rat brain that processes sensory information. After a few months, the team did an experiment that suggested the human cells were reacting to whatever the rat was sensing.
"When you stimulate the whiskers of the rat, the majority of human neurons are engaged in an electrical activity that follows that stimulation," Pasca says.
Another experiment suggests the human cells could even influence a rat's behavior.
The team trained rats to associate stimulation of their human cells with a reward a drink of water. Eventually, the rats began to seek water whenever the human cells were stimulated.
In a final experiment, Pasca's team set out to show how transplanted organoids could help identify the brain changes associated with a specific human disorder. They chose Timothy Syndrome, a very rare genetic disorder that affects brain development in ways that can cause symptoms of autism spectrum disorder.
The team compared organoids made from the stem cells of healthy people with organoids made from the stem cells of patients with the syndrome. In the lab, the cell clusters looked the same.
"But once we transplanted and we looked 250 days later, we discovered that while control cells grew dramatically, patient cells failed to do so," Pasca says.
A better model, with ethical concerns
The experiments show that Pasca's team has developed a better model for studying human brain disorders, Arlotta says.
The key seems to be providing the transplanted organoids with sensory information that they don't get growing in a dish, she says, noting that an infant's brain needs this sort of stimulation to develop normally.
"It's the stuff that we get after we are born," she says, "especially when we begin to experience the world and hear sound, see light, and so on."
But as brain organoids become more like actual human brains, scientists will have to consider the ethical and societal implications of this research, Arlotta says.
"We need to be able to watch it, consider it, discuss it and stop it if we think we think one day we are at the point where we shouldn't progress," she says. "I think we are far, far away from that point right now."
Even the most advanced brain organoids have nothing even remotely like the capabilities of a human brain, says Hyun, who posted a video conversation he had with Pasca to coincide with the publication of the new study.
Yet many ethical discussions have focused on the possibility that an organoid could attain human-like consciousness.
"I think that's a mistake," Hyun says. "We don't exactly know what we mean by 'human-like consciousness,' and the nearer issue, the more important issue, is the well-being of the animals used in the research."
He says that wasn't a problem in the Pasca lab's experiments because the organoids didn't seem to harm the animals or change their behavior.
If human brain organoids are grown in larger, more complex animal brains, Hyun says, the cell clusters might develop in ways that cause the animals to suffer.
"What I'm concerned about," he says, "is what's next."
Originally posted here:
Human neuron clusters transplanted into rats offer new tool to study the brain : Shots - Health News - NPR
Posted in Stem Cells
Comments Off on Human neuron clusters transplanted into rats offer new tool to study the brain : Shots – Health News – NPR
The neuroprotective effects of dental pulp stem cells and erythropoietin in mice hippocampus after ischemia-reperfusion – Newswise
Posted: October 13, 2022 at 2:02 am
Abstract: Background Brain strokes are the cause of death in many people, among survivors; it can cause problems such as motor and cognitive impairment. The role of the hippocampus and its damage in ischemia has been assessed by researchers. One of the treatments commonly used today by researchers in cell therapy. Therefore, this study aimed to evaluate the use of dental pulp stem cells and erythropoietin in mice hippocampus after ischemia-reperfusion. Methods In this study, NMRI male mice were divided into six groups. Except for the sham group, all groups group experienced ischemic hippocampus. A group received erythropoietin or dental pulp stem cells and the other group received a combination exposer of erythropoietin and DPSC, while the vehicle group received DPSC solvent and erythropoietin solvent. After eight weeks, they were subjected to a test of learning and memory by Morris water maze. Then, their brains were examined for histological assessment, and immunohistochemistry (DCX and NeuN for neurogenesis). Furthermore, VEGF was applied for angiogenesis and GFAP for gliosis examination. Results The behavioral function of the group receiving erythropoietin and the combined group (DPSC and erythropoietin) was better than other groups. The mean number of healthy cells in EPO, DPSC, and EPO + DPSC groups was significantly different from that of the vehicle group (P < 0.05). Besides, DPSC, EPO, and EPO + DPSC groups showed a significant increase in green density in comparison with the ischemia and vehicle groups (P < 0.05), but no difference was found between the ischemia and sham groups. Conclusion DPSC and erythropoietin were capable of increased neuronal function but behavioral studies revealed that outcomes of erythropoietin therapy are better than DPSC
Read more from the original source:
The neuroprotective effects of dental pulp stem cells and erythropoietin in mice hippocampus after ischemia-reperfusion - Newswise
Posted in Stem Cells
Comments Off on The neuroprotective effects of dental pulp stem cells and erythropoietin in mice hippocampus after ischemia-reperfusion – Newswise
A $7 million grant to grow stem cell research – Swinburne University of Technology
Posted: October 13, 2022 at 2:02 am
Swinburne University of Technology has received a share of a $7 million Medical Research Future Fund grant to develop first-of-its-kind Australian research to allow live stem cells to be 3D printed and used in treatments.
The cross-institutional research team will develop novel cartilage-based stem cell therapies that will change the way we care for people living with painful joint disease, such as osteoarthritis, and facial disfigurement.
More than two million Australians live with the painful and degenerative joint disease, osteoarthritis, and one in 2,000 newborns are born with microtia an absent or poorly formed ear which can lead to hearing loss, speech and literacy delays.
This research could actually restore damaged or absent cartilage, transforming how these conditions are treated and vastly improving quality of life for sufferers.
It will use technology to revolutionise the way we think about personalised care, patient involvement and scientific advancements.
Cartilage, like that pictured, is a flexible connective tissue that protects our joints and bones
This ambitious project builds on many years of previous research, including at Swinburne.
In the initial stages, the five-year project will focus on the technologies used to take live stem cell printing from research labs into clinical settings. The team will then proceed to clinical trials to prove the efficacy of the solution.
Led by University of Melbourne Professor Peter Choong, the researchers also hope to simplify processes to bring these treatments into hospitals so that clinicians can treat conditions more quickly, with fewer complications than before.
In addition to Swinburne and the University of Melbourne, the research team also includes experts from La Trobe University, St Vincents Hospital Melbourne, University of Wollongong, University of Sydney, Royal Prince Alfred Hospital, Monash University, RMIT and the University of Toronto.
Swinburne will develop a bioreactor system using its patent-protected materials, which allow stem cells to be expanded to large numbers that can be used to repair and replace damaged or missing cartilage.
Expert in biomedical electromaterials science, Professor Simon Moulton, will lead the Swinburne team.
This grant allows us to continue the work we have already been doing with the other partners over many years in developing innovative cartilage repair strategies, says Professor Moulton.
As a materials engineering researcher in the medical area, we do not always have the opportunity to translate our efforts from fundamental research into a clinical human solution. The $7 million of total grant funding will allow us to continue to develop the stem cell technology towards clinical translation that will provide benefit to a wide range of patients.
Here is the original post:
A $7 million grant to grow stem cell research - Swinburne University of Technology
Posted in Stem Cells
Comments Off on A $7 million grant to grow stem cell research – Swinburne University of Technology